tetano
Editor, Senior Moderator
J Virol Methods
. 2021 Sep 22;114300.
doi: 10.1016/j.jviromet.2021.114300. Online ahead of print.
Syndromic approach to SARS-CoV-2 detection using QIAstat-Dx SARS-CoV-2 Panel from clinical samples
Akshita Gupta[SUP] 1 [/SUP], Anushika Soni[SUP] 2 [/SUP], Sheetalnath Rooge[SUP] 3 [/SUP], Diptanu Paul[SUP] 4 [/SUP], Reshu Agarwal[SUP] 5 [/SUP], Bansidhar Tarai[SUP] 6 [/SUP], Ekta Gupta[SUP] 7 [/SUP]
Affiliations
Abstract
The QIAstat-Dx SARS-CoV-2 panel is a multiplex cartridge based assay based on real time PCR which can detect 17 respiratory viruses, including the novel coronavirus SARS-CoV-2. A syndromic approach is the need of the hour for COVID-19 diagnostics among patients presenting with respiratory symptoms. The present study was done to evaluate 120 archived respiratory clinical specimens for SARS-CoV-2 on the SARS-CoV-2 panel. Further, 27 specimens were tested for other respiratory viruses, in comparison with the BioFire RP1.7 platform. The sensitivity and specificity for SARS-CoV-2 on SARS panel was found to be 90.00% and 100% respectively, indicating good diagnostic accuracy. The positive predictive value was found to be 100%, negative predictive value was found to be 99.93% and accuracy was 99.93%. Detection of other respiratory viruses observed a concordance of 77.7%. Despite advantages of speed, minimal expertise and accurate results; significant costs and discrepancies at Ct >35 remain important limitations of the SARS panel.
Keywords: CBNAAT; COVID-19; Point of care; clinical evaluation; diagnostics.
. 2021 Sep 22;114300.
doi: 10.1016/j.jviromet.2021.114300. Online ahead of print.
Syndromic approach to SARS-CoV-2 detection using QIAstat-Dx SARS-CoV-2 Panel from clinical samples
Akshita Gupta[SUP] 1 [/SUP], Anushika Soni[SUP] 2 [/SUP], Sheetalnath Rooge[SUP] 3 [/SUP], Diptanu Paul[SUP] 4 [/SUP], Reshu Agarwal[SUP] 5 [/SUP], Bansidhar Tarai[SUP] 6 [/SUP], Ekta Gupta[SUP] 7 [/SUP]
Affiliations
- PMID: 34562514
- DOI: 10.1016/j.jviromet.2021.114300
Abstract
The QIAstat-Dx SARS-CoV-2 panel is a multiplex cartridge based assay based on real time PCR which can detect 17 respiratory viruses, including the novel coronavirus SARS-CoV-2. A syndromic approach is the need of the hour for COVID-19 diagnostics among patients presenting with respiratory symptoms. The present study was done to evaluate 120 archived respiratory clinical specimens for SARS-CoV-2 on the SARS-CoV-2 panel. Further, 27 specimens were tested for other respiratory viruses, in comparison with the BioFire RP1.7 platform. The sensitivity and specificity for SARS-CoV-2 on SARS panel was found to be 90.00% and 100% respectively, indicating good diagnostic accuracy. The positive predictive value was found to be 100%, negative predictive value was found to be 99.93% and accuracy was 99.93%. Detection of other respiratory viruses observed a concordance of 77.7%. Despite advantages of speed, minimal expertise and accurate results; significant costs and discrepancies at Ct >35 remain important limitations of the SARS panel.
Keywords: CBNAAT; COVID-19; Point of care; clinical evaluation; diagnostics.